- Home
- AKBA vs NCV Comparison
AKBA vs NCV Comparison
Compare AKBA & NCV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKBA
- NCV
- Stock Information
- Founded
- AKBA 2007
- NCV 2003
- Country
- AKBA United States
- NCV United States
- Employees
- AKBA N/A
- NCV N/A
- Industry
- AKBA Biotechnology: Pharmaceutical Preparations
- NCV Finance Companies
- Sector
- AKBA Health Care
- NCV Finance
- Exchange
- AKBA Nasdaq
- NCV Nasdaq
- Market Cap
- AKBA 336.2M
- NCV 326.2M
- IPO Year
- AKBA 2014
- NCV N/A
- Fundamental
- Price
- AKBA $1.91
- NCV $3.51
- Analyst Decision
- AKBA Strong Buy
- NCV
- Analyst Count
- AKBA 1
- NCV 0
- Target Price
- AKBA $7.50
- NCV N/A
- AVG Volume (30 Days)
- AKBA 2.2M
- NCV 405.1K
- Earning Date
- AKBA 11-07-2024
- NCV 01-01-0001
- Dividend Yield
- AKBA N/A
- NCV 12.48%
- EPS Growth
- AKBA N/A
- NCV N/A
- EPS
- AKBA N/A
- NCV N/A
- Revenue
- AKBA $169,879,000.00
- NCV N/A
- Revenue This Year
- AKBA N/A
- NCV N/A
- Revenue Next Year
- AKBA $30.85
- NCV N/A
- P/E Ratio
- AKBA N/A
- NCV N/A
- Revenue Growth
- AKBA N/A
- NCV N/A
- 52 Week Low
- AKBA $0.80
- NCV $2.84
- 52 Week High
- AKBA $2.48
- NCV $3.59
- Technical
- Relative Strength Index (RSI)
- AKBA 49.15
- NCV 44.69
- Support Level
- AKBA $1.74
- NCV $3.62
- Resistance Level
- AKBA $1.90
- NCV $3.61
- Average True Range (ATR)
- AKBA 0.08
- NCV 0.06
- MACD
- AKBA -0.02
- NCV -0.02
- Stochastic Oscillator
- AKBA 34.38
- NCV 25.00
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
About NCV Virtus Convertible & Income Fund of Beneficial Interest
Virtus Convertible & Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide total return through a combination of capital appreciation and high current income. It intends to achieve the objective by investing in a portfolio of domestic convertible securities and non-convertible income-producing securities. Its portfolio of investments includes Software, the Internet, the Commercial Services sector in the form of Convertible Bonds and Notes, and Media, Oil, Gas & Consumable Fuels, and Entertainment sector in the form of Corporate Bonds and Notes.